Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria Vaccines
Research from S.J. Jordan and co-researchers in the area of malaria vaccines described
April 22nd, 2009
According to recent research published in the American Journal of Tropical Medicine and Hygiene, "The N-terminal domain of Plasmodium falciparum merozoite surface protein-3 (PfMSP3) has been excluded from malaria vaccine development largely because of genetic diversity concerns. However, no study to date has followed N-terminal diversity over time." "This study describes PfMSP3 variation in a hypoendemic longitudinal cohort in the Peruvian Amazon over the 2003-2006 transmission seasons. Polymerase chain reaction was used to amplify the N-terminal domain in 630 distinct P falciparum infections, which were allele-typed by size and also screened for sequence...
Source: Vaccine Weekly (2009-04-22)
|
